Loading organizations...
Zoo Capital operates as a venture capital platform, investing in early-stage companies across global technology and life sciences. The firm partners with entrepreneurs, providing capital and strategic support to foster sustainable growth. It leverages deep analysis of business fundamentals and emerging industry trends to back high-potential, innovative enterprises.
Founded in 2020, Zoo Capital originated from entrepreneurial professionals recognizing the transformative potential of frontier technologies. Affiliated with Boyu Capital, the firm maintains a clear mission to foster early-stage innovation. Its inception underscores a commitment to deploying diverse expertise in identifying and developing promising companies.
The firm primarily serves exceptional startups and business leaders aspiring to scale their ventures. Zoo Capital’s long-term vision is to deliver compelling returns to investors through a portfolio of dynamic companies. Beyond financial objectives, it seeks to generate positive societal impact, advancing critical global industries via strategic investments.
Zoo Capital has 6 tracked investments across 5 companies. The latest tracked deal is $3.2M Seed in TabbyML in October 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 10, 2023 | TabbyML | $3.2M Seed | — | Yunqi Partners |
| Jun 13, 2023 | Positive Sequence Biology | $5.6M Other Equity | ZOO Capital | — |
| Mar 27, 2023 | ArriVent Biopharma | $155.0M Series B | Elena Viboch, James Healy | Aihc Capital, Catalio Capital, HBM Healthcare Investments, Hongshan Capital Group (Sequoia Capital China), Infinitum Asset Management, Lilly Asia Ventures, Octagon Capital, Carl Gordon, Shanghai Healthcare Capital, Sirona Capital, Terra Magnum Capital Partners, Unicorn Capital |
| Nov 1, 2021 | CyberConnect | $10.0M Seed | Multicoin Capital, Sky9 Capital | Animoca Brands, Infinity Ventures Crypto, Sebastien Borget, Draper Dragon, Hashed, Mask Network, Smrti LAB |
| Jun 30, 2021 | ArriVent Biopharma | $150.0M Series A | Hillhouse Capital Group | Lilly Asia Ventures, Lyra Capital, Octagon Capital, OrbiMed |
| Dec 1, 2020 | SciNeuro | $100.0M Series A | ARCH Venture Partners, Judith LI | Sequoia Capital China, Boyu Capital, General Atlantic, Hongshan Capital Group (Sequoia Capital China), TF Capital |